Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — H1 2026 Earnings Presentation
28 slides from Imricor Medical Systems's earnings presentation, Aug 10, 2026
Slide 1: 1H 2026 Investor Presentation
1H 2026 Investor Presentation August 10th 2026 Imricor's vision is to bring iMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 1
Slide 2: Disclaimer
Disclaimer The material contained in this document is a presentation of general background developments and their potential effect upon Imricor. There can be no assurance that future information on Imricor Medical Systems, Inc. (Imricor) and its activities current as of the date developments will be
Slide 3: Contents
Contents • Imricor in 60 seconds • Key highlights • The problem with X-ray • Regulatory momentum • NorthStar & U.S. Commercial Launch • 1H 26 financial results • Looking ahead to 2H 26 and beyond IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 3
Slide 4: Imricor in 60 seconds
Imricor in 60 seconds The only company in the world supplying the toolset required to perform cardiac ablations and other cardiac catheterisations inside an iMR lab. What we make 1 Capital equipment, software and single-use consumables engineered to function safely and effectively inside a magnetic
Slide 5: 1H 2026 Key highlights
1H 2026 Key highlights 4 ALL US$70m/A$100m* FDA clearances secured in 1H26 remaining 510(k) devices now submitted** net cash — funded into CY2028 CLINICAL REGUL ATORY • VCU and Oklahoma Heart added to the VISABL-AFL FDA CLEARANCES — 4 clinical trial Vision-MR Diagnostic Catheter — 510(k) cleared •
Slide 6: A new era is here for image guided therapies
A new era is here for image guided therapies Radiation-free, real-time soft tissue visualization — the capability an x-ray cath lab cannot deliver From inferring To visualizing Radiation exposure → No radiation Lead protection required → No lead aprons No soft tissue visible under x-ray → Soft tissu
Slide 7: Ionizing Radiation: Shield or Remove
Ionizing Radiation : Shield or Remove JULY 2026 — SIX SOCIETIES CALL FOR 'M ANDATORY AND URGENT ACTION' JULY 14, 2026 Shielding the Operator Is Not the Same as Six Medical Societies Call for Immediate Adoption of Enhanced Radiation Protection in Removing the Radiation Fluoroscopy Labs 2,500–10,000 8
Slide 8: Regulatory momentum
Regulatory momentum Earning the right to treat patients IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 8
Slide 9: Regulatory progress: FY25 result vs 1H26 result
Regulatory progress: FY25 result vs 1H26 result A stand out half of regulatory progress – few companies have ever pushed a platform of this scale through FDA approval at once UNITED STATES — device / submission Pathway STATUS AT FY25 RESULT (Feb 2026) STATUS AT 1H26 RESULT (Aug 2026) NorthStar 510(k
Slide 10: Cardiac MR is a structurally growing field
Cardiac MR is a structurally growing field Society for Cardiovascular Magnetic Resonance (SCMR) Annual Scientific Sessions, 1998–2025 Delegates attending annual sessions 1,800 1,714 +535% 1,524 Attendance growth 1,406 1,440 270 delegates (1998) to 1,714 delegates (2025) 1,200 1,100 +643% Accepted ab
Slide 11: Imricor Cardiovascular: A New Vertical
Imricor Cardiovascular : A New Vertical Extending real-time MR guidance from electrophysiology into cardiac catheterisation NEW VERTICAL THE EC ONO MI C CASE — iMR - GUID ED R IGH T H EAR T CATH Launched July 2026 One MR session replaces two. In-facility minutes per patient Per-patient procedural ti
Slide 12: Imricor Cardiovascular: A New Growth Engine
Imricor Cardiovascular : A New Growth Engine A new segment that drives NorthStar sales, licence revenue and consumables pull-through NEW VERTICAL HOW THE REVENUE BUILDS New growth segment One NorthStar sale, three revenue streams Each NorthStar sale creates one new installed lab A new growth engine
Slide 13: Electrophysiology: iMR Lab Economics
Electrophysiology : iMR Lab Economics How recurring revenue builds at each new customer lab ONE-TIME RECU RRI NG — EVERY YEAR Capital revenue Consumable revenue per lab, built from procedure mix Atrial Flutter 100 × US$4.0k $3.0m $0.40m US$500k–700k VT 100 × US$6.5k + $2.0m $0.65m per lab installati
Slide 14: Delivering key milestones in 1H 2026
Delivering key milestones in 1H 2026 Regulatory & Clinical Commercial Financial • FDA paediatric clearance — NorthStar • U.S. launch commenced — Rady • A$60m placement completed at A$1.85 and Vision-MR Diagnostic Catheter now Children's San Diego is first U.S. per CDI cleared for all ages customer •
Slide 15: Financial Performance
Financial Performance IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 15
Slide 16: Profit and loss
Profit and loss US$’000 Q2 2026 Q2 2025 Commentary Revenue 61 65 • Revenue flat on prior comparative period (pcp) is the result of customer sites continuing to enrol trial patients. Costs and non-R&D expenses (3,725) (2,792) • Costs and non-R&D expenses increased primarily due to R&D expenses (3,611
Slide 17: Balance sheet
Balance sheet US$’000 30 Jun 2026 31 Dec 2025 Cash and cash equivalents 60,539 19,502 Commentary Marketable securities 6,922 21,278 • Cash, cash equivalents, and marketable securities balances Accounts receivable 255 241 total $67.5 million Inventory 1,346 1,096 • Convertible note held at fair value
Slide 18: Cash flow
Cash flow US$’000 Q2 2026 Q2 2025 Commentary Net loss (7,382) (7,795) • Other non-cash adjustments decrease vs. pcp primarily due Other non-cash adjustments 921 3,316 to decreases in the change in fair value charges. • Proceeds from issuance of common stock in Q2 26 reflect Change in other assets an
Slide 19: Looking ahead to 2H 2026 & into 2027
Looking ahead to 2H 2026 & into 2027 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 19
Slide 20: The largest and fastest growing market in MedTech
The largest and fastest growing market in MedTech1 A large global addressable market with high growth supported by favourable growth drivers Drivers of global catheter ablation market Electrophysiology Device Market (US$bn) 70 59.8 60 Increased incidence of cardiac disease 52.0 50 15% CAGR 45.2 39.3
Slide 21: Several key value drivers during 2H 2026 and beyond
Several key value drivers during 2H 2026 and beyond FDA decisions on remaining submissions New Philips site activations following receipt to complete the US platform of Declaration of Compatibility • Multiple 510(k) clearances • VISABL-AFL clinical trial completion. • Final PMA submission / approval
Slide 22: Questions?
Questions? IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 22
Slide 23: Appendix – Additional Information
Appendix 1 – Additional Information IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 23
Slide 24: VISABL-AFL Clinical Trial Sites
VISABL-AFL Clinical Trial Sites DR. AV KOLANDAIVELU DR. AJAY PILLAI DR. MARCO GÖTTE PROF. JUERG SCHWITTER Johns Hopkins University Virginia Commonwealth University Health Amsterdam University Medical Center MD, Director Cardiac MR Centre, University Hospital Lausanne (CHUV) “MRI is the gold standard
Slide 25: A strong intellectual property portfolio
A strong intellectual property portfolio Imricor’s patents protect technology that allows Imricor to manufacture medical devices that are uniquely MRI compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor. 21 issued U.S patents In ad
Slide 26: Imricor Leadership: Management
Imricor Leadership: Management STEVE WEDAN JONATHON GUT NICK CORKILL JENNIFER WEISZ VIC FABANO President and Chief Executive Officer, Vice President of Finance and Chief Vice President of Corporate Strategy Vice President of Regulatory and Vice President of Operations and Board Chair Financial Offic
Slide 27: Imricor Leadership: Board of directors
Imricor Leadership: Board of directors STEVE WEDAN MARK TIBBLES PETER MCGREGOR ANITA MESSAL JEFFREY LEIGHTON ALDO DENTI President and Chief Executive Deputy Chair and Lead Non-executive Director Non-executive Director Non-executive Director Non-executive Director Officer, and Board Chair Independent
Slide 28: Contact information
Contact information Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.corkill@imricor.com Res
Imricor Medical Systems — H1 2026 Earnings Presentation on 6ix